Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia

Urology

Volumn 68, Issue 2, 2006, Pages 328-332

  Kaplan, Steven A ^a   Roehrborn, Claus G ^b   Dmochowski, Roger ^c   Rovner, Eric S ^d   Wang, Joseph T ^e   Guan, Zhonghong ^e  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOLTERODINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MICTURITION DISORDER; NAUSEA; NOCTURIA; OVERACTIVE BLADDER; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY INCONTINENCE; URINATION DISORDERS;

EID: 33746811410     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.03.006     Document Type: Article

References (24)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function. report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
3. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
4. Girman C.J., Jacobsen S.J., Tsukamoto T., et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51 (1998) 428-436
5. Hyman M.J., Groutz A., and Blaivas J.G. Detrusor instability in men. correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166 (2001) 550-553
6. Fusco F., Groutz A., Blaivas J.G., et al. Videourodynamic studies in men with lower urinary tract symptoms. a comparison of community based versus referral urological practices. J Urol 166 (2001) 910-913
7. Greenland J.E., and Brading A.F. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 165 (2001) 245-248
8. Harrison S.C., Hunnam G.R., Farman P., et al. Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 60 (1987) 519-522
9. Mirone V., Imbimbo C., Sessa G., et al. Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J Urol 172 (2004) 1386-1389
10. Seki N., Karim O.M., and Mostwin J.L. Changes in electrical properties of guinea pig smooth muscle membrane by experimental bladder outflow obstruction. Am J Physiol 262 (1992) F885-F891
11. Jumadilova Z., Harris H., del Aguila M., et al. Agent selection for overactive bladder patients with and without documented comorbid benign prostatic hyperplasia (read by title) (2005), Presented at the International Continence Society Meeting, Montreal, Canada August 28 to September 2
12. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
13. Ignjatovic I. Symptoms and urodynamics after unsuccessful transurethral prostatectomy. Int Urol Nephrol 32 (2001) 655-658
14. Appell R.A., Abrams P., Drutz H.P., et al. Treatment of overactive bladder. long-term tolerability and efficacy of tolterodine. World J Urol 19 (2001) 141-147
15. van Kerrebroeck P., Kreder K., Jonas U., et al. Tolterodine once-daily. superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
16. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 (2005) 2273-2276
17. Athanasopoulos A., Gyftopoulos K., Giannitsas K., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction. a prospective, randomized, controlled study. J Urol 169 (2003) 2253-2256
18. Abrams P., Kaplan S.A., de Koning Gans H.J., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 (2006) 999-1004
19. Hu T.W., Wagner T.H., Bentkover J.D., et al. Costs of urinary incontinence and overactive bladder in the United States. a comparative study. Urology 63 (2004) 461-465
20. Serels S. The wet patient. understanding patients with overactive bladder and incontinence. Curr Med Res Opin 20 (2004) 791-801
21. Nixon A., Colman S., Sabounjian L., et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174 (2005) 604-607
22. Jonas U., Hofner K., Madersbacher H., et al., International Study Group. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency. urodynamic evaluation. World J Urol 15 (1997) 144-151
23. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2 (2001) 1685-1701
24. Homma Y., Paick J.S., Lee J.G., et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder. a randomized, placebo-controlled trial. BJU Int 92 (2003) 741-747